MedTrace Logo

Megakaryocyte Heterogeneity in Sickle Cell Disease

NCT06850337 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2025-05-25

No results posted yet for this study

Summary

Sickle cell disease (SCD) is characterized by chronic hemolytic anemia, painful crisis called vaso-occlusive crisis (VOC) and chronic inflammation. Activated platelets of SCD patients participated to both chronic inflammation and painful VOC. Platelets are anucleated cells from the fragmentation of megakaryocytes in bone marrow.

The main aim of this study is to characterize the distribution of the different megakaryocyte subpopulations of sickle cell disease patients SS and SC and in particular the "immune" megakaryocytes CD148+CD48+ and to compare it with the platelet phenotype.

Conditions

  • Sickle Cell Disease (SCD)

Sponsors & Collaborators

  • Centre Hospitalier Universitaire de la Guadeloupe

    lead OTHER

Principal Investigators

  • Veronique Baccini, MD PhD · CHU de la Guadeloupe

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-07-31
Primary Completion
2027-03-31
Completion
2027-03-31

Countries

  • Guadeloupe

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06850337 on ClinicalTrials.gov